Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l'Ouest to evaluate efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor- positive (HR 1 ) metastatic breast cancer (MBC) pretreated with everolimus

Trial Profile

Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l'Ouest to evaluate efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor- positive (HR 1 ) metastatic breast cancer (MBC) pretreated with everolimus

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2017 New trial record
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top